国产奎硫平与利培酮治疗首发精神分裂症对照研究

A control study on national quetiapine and risperidone in first-episode schizophrenia

目的比较奎硫平与利培酮治疗首发精神分裂症的疗效和安全性。方法将60例首发精神分裂症患者随机分为奎硫平治疗组和利培酮治疗组各30例,奎硫平治疗平均剂量为650±117mg·d-1,利培酮治疗平均剂量为4.0±1.8mg·d-1,疗程均为8w。于治疗前及治疗第2、4、6、8w末采用阳性和阴性症状量表、副反应量表评定临床疗效及不良反应。结果奎硫平治疗显效率为76.7%,利培酮为70%,两组差异无显著性(P>0.05),疗效相当;两组多在用药初期出现不良反应,且发生率较低,程度较轻,均可耐受,经对症处理后均可缓解或消失。结论奎硫平与利培酮治疗首发精神分裂症的疗效相当。

Objective To compare safe and curative effect of national quetiapine and risperidone for firstepisode schizophrenics. Methods 60 first-episode schizophrenics were randomly divided into quetiapine group（n=30,treated with quetiapine, mean dose 650＋ llTmg/d） and risperidone group（n=30, treated with risperidone, mean dose 4. 0±1.8mg/d）, treated for 8 weeks. The curative effect and side effect were assessed with positive and negative syndrome scale （PANSS） and treatment emergency symptom scale （TESS） respectively before treatment and at the end of 2w,4w,6w,8w. Results The curative effect rates of quetiapine and risperidone were 76.7% and 70% respective, there was not different between them. Both groups showed side effects at initial stage, but the side effects were mild and their accidence low. After treatment, the side effects could relieve or disappear. Conclusion Quetiapine and risperidone have equivalent curative effect for first-episode schizophrenia.